It also provides a comparison to AQP4-seropositive NMOSD. This part explores the course of disease and outcomes. Part 1 of 4 of a large multicenter retrospective study of MOG-AD. Part 1: frequency, syndrome specificity, influence of disease activity, long-term course, association with AQP4-IgG, and origin. MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Jarius S, Ruprecht K, Kleiter I, Borisow N, Asgari N, Pitarokoili K et al.One of the largest MOG-AD cohort studies, which outlined the clinical presentation of MOG-AD and differentiated it from MS. Clinical presentation and prognosis in MOG-antibody disease: a UK study. Jurynczyk M, Messina S, Woodhall MR, Raza N, Everett R, Roca-Fernandez A, et al.A large cohort of MOG-AD patients, illustrating the wide spectrum of MOG-AD. Clinical spectrum and prognostic value of CNS MOG autoimmunity in adults. Cobo-Calvo A, Ruiz A, Maillart E, Audoin B, Zephir H, Bourre B, et al.This part focuses on brainstem presentations as part of the MOG-AD spectrum. Part 3 of 4 of a large multicenter retrospective study of MOG-AD. Part 3: brainstem involvement - frequency, presentation and outcome. Jarius S, Kleiter I, Ruprecht K, Asgari N, Pitarokoili K, Borisow N et al.MOG antibody-related disorders: common features and uncommon presentations. Clinical spectrum associated with MOG autoimmunity in adults: significance of sharing rodent MOG epitopes. Sepúlveda M, Armangue T, Martinez-Hernandez E, Arrambide G, Sola-Valls N, Sabater L, et al. This part focuses on clinical presentation, radiological features, treatment, and outcomes. Part 2 of 4 of a large multicenter retrospective study of MOG-AD. Part 2: epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and long-term outcome. Jarius S, Ruprecht K, Kleiter I, Borisow N, Asgari N, Pitarokoili K, et al.A review of MOG-AD with focus on practical aspects, such as diagnosis, treatment, and prognosis. Myelin oligodendrocyte glycoprotein (MOG) antibody-associated disease: practical considerations. Juryńczyk M, Jacob A, Fujihara K, Palace J.Myelin-oligodendrocyte glycoprotein antibodies in adults with a neuromyelitis optica phenotype. Kitley J, Woodhall M, Waters P, Leite MI, Devenney E, Craig J, et al. Neuromyelitis optica spectrum disorders with aquaporin-4 and myelin-oligodendrocyte glycoprotein antibodies. Kitley J, Waters P, Woodhall M, Leite MI, Murchison A, George J, et al. Distinction between MOG antibody-positive and AQP4 antibody-positive NMO spectrum disorders. Sato DK, Callegaro D, Lana-Peixoto MA, Waters PJ, Jorge FMDH, Takahashi T, et al. Myelin oligodendrocyte glycoprotein: deciphering a target in inflammatory demyelinating diseases.
Peschl P, Bradl M, Höftberger R, Berger T, Reindl M. A review of MOG-AD, with focus on molecular, radiological, and clinical aspects. Myelin oligodendrocyte glycoprotein antibodies in neurological disease. Papers of particular interest, published recently, have been highlighted as: The development of targeted therapies is expected in the future as the pathogenesis of MOG-IgG becomes better understood. However, there is limited consensus on the best long-term immunotherapy and prospective studies are needed to compare the efficacy of different agents. IVMP followed by a prolonged prednisone taper is the mainstay of acute management. Disease-modifying therapies (DMTs) typically used for multiple sclerosis (MS) are avoided. Rituximab, azathioprine, mycophenolate mofetil, and IVIG have all been used. There are yet to be any prospective trials for selection of the most appropriate agent. Long-term immunotherapy is reserved for patients with relapsing or severely disabling disease. This is typically followed by a prolonged oral prednisone taper. Acutely, 1 g daily of intravenous methylprednisolone (IVMP) for 3–5 days has been associated with better outcomes for optic neuritis. Recent findingsĪs commercial testing for MOG-IgG did not become widely available until 2016, most of the evidence concerning management is from retrospective observational studies. We will also present recommendations for initiation of long-term immunotherapy for patients with a relapsing course and discuss our approach for monitoring disease progression and escalation of therapy. We will focus on evidence-based management options in the acute setting. This review offers a look into available treatment strategies for patients with MOG-IgG associated disease (MOG-AD).
0 kommentar(er)
